Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 12, No. 1, 2013, pp. 1-6
Bioline Code: pr13001
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 12, No. 1, 2013, pp. 1-6
© Copyright 2013 - Tropical Journal of Pharmaceutical Research
Preparation, Characterisation and In Vivo Evaluation of Silybin Nanoparticles for the Treatment of Liver Fibrosis|
Bonepally, Chandrasekhar R.; Gandey, Sai Jyothsna; Bommineni, Krishnaveni; Gottumukkala, Krishna Mohan & Aukunuru, Jithan
Purpose: To formulate and characterize nanoparticles containing silybin, and evaluate their activity
against carbon tetrachloride (CCl4)-induced liver toxicity.
Methods: Silybin nanoparticles were formulated by o/w emulsion solvent evaporation technique using
poly-ε-caprolactone as polymer. Four different nanoparticle formulations (NP1, NP2, NP3 and NP4) were
prepared by varying the drug/polymer ratio. The particles were characterized for particle size, drug
content and in vitro drug release. The pharmacokinetics and pharmacodynamics of the silybin
formulations in male Wistar rats were evaluated following i.v. administration, using silybin solution as
reference. The hepatoprotective activity of the formulations was also determined in a CCl4-treated rat
Results: Silybin nanoparticles were successfully prepared using o/w emulsion solvent evaporation
technique. The nanoparticles sustained the release of the drug both in vitro and in vivo for up to 10 days
and offered better pharmacokinetic properties than the free drug itself. Intravenous nanoparticulate
administration reversed serum liver enzyme levels by 95 % compared to only 50 % for the drug solution.
Conclusion: The developed silybin nanoparticles showed superior pharmacokinetic properties and
hepatoprotective activity to silybin solution.
Silybin, Nanoparticles, Pharmacokinetics, Pharmacodynamics, Hepatoprotective activity.
Alternative site location: http://www.tjpr.org